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Abstract
Pulmonary aspergillosis is a condition caused by the fungi Aspergillus. The form of disease depends on the immunological con-
dition of the host organism and other concomitant illnesses that influence the pulmonary tissue. Asthmatic patients, in particular 
with the severe form of disease, who require the use of systemic glucocorticoids, are predisposed to develop allergic bronchopul-
monary aspergillosis. Development of aspergilloma in the lung is preceded by the formation of pathological cavity in the course of 
another illness. The study reports a case of a severe asthma patient who developed aspergilloma in atypical localisation, without 
the presence of predisposing anatomical changes and illnesses.
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Introduction
Pulmonary aspergillosis is caused by a fun-
gus of the genus Aspergillus, most frequently by 
Aspergillus fumigatus. This type of fungi is wi-
despread in nature, therefore exposure to them 
is very common. Small size of spores, resistance 
to extreme environmental conditions together 
with high prevalence, enable them to reach the 
pulmonary alveoli [1−3]. Development of vario-
us pathological syndromes depends on mutual 
reaction of the fungus and immunological sys-
tem of the organism. In the case of persons with 
impaired immunological system, patients with 
neoplasms of the haematopoietic system and 
cachectic patients, invasive aspergillosis may 
develop. Aspergilloma is a noninvasive form of 
infection with Aspergillus. It may complicate di-
seases in the course of which abnormal cavities 
in the lung form, such as tuberculosis, ankylosing 
spondylitis, bronchiectasis or bronchogenic cysts. 
People with atopy and asthma, and those 
with cystic fibrosis develop allergic bronchopul-
monary aspergillosis [1, 4−6]. Hypersensitivity to 
the antigen of Aspergillus, defined as immediate 
cutaneous reaction, occurs in approximately 28% 
of asthma patients. Among the persons with hy-
persensitivity to the antigen of Aspergillus, only 
40% of people meet diagnostic criteria of allergic 
bronchopulmonary aspergillosis [7]. Hypersen-
sitivity to the antigen of Aspergillus develops as 
a result of ciliary clearance disorders and impa-
ired removal of conidia from the airways. 
The literature reported patients in whom 
allergic bronchopulmonary aspergillosis prece-
ded the occurrence of aspergilloma or the two 
conditions coexisted. Immunological reaction 
to the antigen of Aspergillus in patients with 
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asthma and cystic fibrosis results in increased 
mucus production in the airways, which leads to 
obstruction of the bronchi and dilation of their 
lumen. Sporadically, such a process may finish 
in the development of aspergilloma in the cavity 
that was formed secondarily [8−10]. 
The present paper reports the case of the 
patient with severe bronchial asthma, in whom 
in the left lower lobe aspergilloma was detec-
ted, but no anatomical changes predisposing to 
developing cavities in the lungs were observed 
earlier. The criteria required to diagnose allergic 
bronchopulmonary aspergillosis were not met. 
Case report
A male patient, 51 years of age, with diagno-
sed 10 years earlier asthma, was admitted to the 
pulmonological ward in June 2015 due to failure 
to achieve control of the disease in outpatient 
setting. Since diagnosis of asthma, the patient 
remained under the care of the outpatient clinic 
of lung diseases. He had 2−3 asthma exacerba-
tions during the year that required hospitalisation 
and the systemic use of glucocorticoids. In order 
to control symptoms and reduce the number of 
exacerbations, he used oral prednisone and me-
thylprednisolone at the doses corresponding to 30 
mg of prednisone. The use of glycocorticosteroids 
was complicated by cataract of both eyes — the 
patient underwent phacoemulsification and im-
plantation of artificial lens to the left and right 
eyeball 6 years ago — and osteoporosis together 
with fracture of lumbar and costal vertebrae. 
Moreover, one year ago the patient underwent 
ischaemic stroke of the left cerebral hemisphere 
with retreating right-sided paresis. In the course 
of neurological evaluation chronic inflammatory 
changes in the maxillary sinuses were discovered.
At the admission to the ward the patient re-
ported cough with expectoration of purulent spu-
tum and dyspnoea attacks with wheezing despite 
the use of inhaled budesonide and formoterol at 
the doses of 320 ug and 9 ug respectively twice 
a day, theophylline at the dose of 300 mg per 
day, montelukast at the dose of 10 mg daily and 
methyloprednisolone at the dose of 4 mg daily. 
In addition, during exacerbations of the disease 
the patient noticed that expectorated sputum was 
periodically stained with blood. 
Physical examination identified the follo-
wing deviations: weaker sensation on the right 
side of the body, weaker muscle strength on the 
right side to 4/5 in the Lovett scale and increased 
tendon and periosteal reflexes at the right side. 
Laboratory tests showed as follows: morphology 
with no significant deviations from the norm, li-
ver and kidneys function was within the normal 
levels, parameters of inflammatory state (CRP, 
leucocytosis) were normal. IgE concentration was 
determined > 2500 IU/ml. Scatoscopy did not 
reveal parasites. Spirometry discovered obstruc-
tion, FEV1/FVC after the use of beta-mimetic was 
52% of predicted with FEV1 amounting to 44% 
of predicted. Arterial blood gases did not show 
features of respiratory failure.
Skin prick tests showed allergy to dog and 
cat hair, tree and weed pollen.
Chest radiograph was performed revealing 
oval focal lesion measuring 25 × 23 mm in the 
left lower lobe (Fig. 1). Computed tomography of 
the chest was carried out (June 22, 2015) showing 
in the left lower lobe a cavity measuring 31 × 39 
mm in the transverse plane, within which soft 
tissue structure measuring 17 × 25 mm, which 
could correspond to aspergilloma, was detected 
(Fig. 2). Computed tomography performed 5 years 
ago had not shown pathological lesions in the 
mentioned site (Fig. 3). CT scans did not reveal 
bronchiectasis or infiltrations in the lung tissue.
As radiological image corresponded to as-
pergilloma, bronchofiberoscopy was performed. 
No pathology was visualized except reddening of 
the mucous membrane. Specimen was taken from 
the left lower lobe for mycological, cytological 
and bacteriological testing, including tests tar-
geted at tuberculosis. Cytological examination of 
Figure 1. Chest radiograph — 25 × 23 mm focal lesion in the lower, 
left lobe
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Figure 2. Chest computed tomography — 31 × 39 mm cavity with 17 × 25 mm soft tissue structure in the lower, left lobe
Figure 3. Chest computed tomography — no changes in region corresponding to Aspergilloma cavity in Figure 2
bronchial washings discovered purulent exudate. 
Bacterioscopy and PCR testing did not confirm 
mycobacteria in the collected material. They 
were not found neither in cultures using BACTEC 
MGIT 960 system nor the Lowenstein-Jensen 
medium. Quantiferon test gave a negative result. 
Mycological examination of bronchial wa-
shings showed the presence of filamentous fungi 
of morphological features of Aspergillus sp. Myco-
logical diagnosis was supplemented with determi-
nation of circulating antigen of Aspergillus, giving 
a positive result. Moreover, with the help of the 
5 moulds panel, allergen-specific immunoglobu-
lin E was determined. For Aspergillus fumigatus 
it was 4.69 kU/L. The levels of allergen-specific 
immunoglobulin E for the remaining moulds 
(Alternaria tenuis, Penicilium notatum, Cladosporium 
herbarum, Candida albicans) were below 0.1 kU/L.
Due to diagnosis of aspergillosis, blood se-
rum was checked for HIV infection markers 
(4th generation test). Anti-HIV antibodies and p24 
HIV antigen were not detected.
Pharmacotherapy with itraconazole at the 
dose of 200 mg daily was introduced. The patient 
was referred to a thoracic surgery clinic in order 
to be evaluated for surgical treatment.
Discussion
Aspergillus fumigatus is a pathogen that 
causes a series of syndromes ranging from sa-
prophytic to invasive forms, which are defined 
by the influence of the pathogen and immunolo-
gical reaction of the organism. Depending on the 
actual condition of the immunological system, 
the form of disease may change. Aspergilloma 
is a noninvasive form of aspergillosis that de-
velops in the cavities in the lung parenchyma 
in persons without immunity disorders. One 
of the most frequent conditions leading to for-
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mation of cavities colonized by Aspergillus sp. is 
tuberculosis. In the Portuguese study, half of the 
subjects with aspergilloma reported the history of 
tuberculosis, whereas in the group studied by the 
Japanese authors, tuberculosis was diagnosed in 
72% of patients [1, 11−13] In the reported patient, 
imaging examination including chest computed 
tomography performed during the current stay in 
hospital and the one carried out during the previous 
stay did not detect changes suggesting active tuber-
culosis or post-granulomatous changes. Imaging 
examinations conducted prior to hospitalization 
did not reveal pathological cavities, bronchodila-
tation or radiological features that could lead to the 
development of such changes. Bacteriological inve-
stigations, genetic tests or Quantiferon test did not 
show infection with Mycobacterium tuberculosis.
Tuberculosis most often involves the upper 
lobes, therefore the most frequent localisation 
of post-tuberculous cavities which aspergilloma 
colonizes, are the upper lobes [14]. Thus localisa-
tion of changes in the reported patient is atypical, 
as the focal change on chest radiograph is visible 
in the lower lobe.
The presence of aspergilloma is also typical 
of another disease entity — chronic necrotising 
aspergillosis, also called semi-invasive pulmona-
ry aspergillosis. In this form of disease, although 
invasion does not affect vessels, in moderately 
immunosuppressed persons or those with chro-
nic lung disease or with systemic disease such 
as diabetes or rheumatoid arthritis, which di-
sturb immunity topically, the lung parenchyma 
is damaged. The patients complain about fever, 
chronic productive cough, haemoptysis with 
varying intensity and weight loss. In the repor-
ted case, fever or weight loss were not observed. 
Over time, in 50% of patients with semi-invasive 
pulmonary aspergillosis, due to destructed lung 
parenchyma, the cavities and aspergilloma may 
occur, although initially there were no anatomical 
predispositions towards aspergilloma. Imaging 
examinations show consolidation, the thickened 
pleura and cavernous lesions, which, similarly 
to pulmonary tuberculosis, have predilection for 
the upper lobes [15, 16]. Denning et al. proposed 
that, apart from the above mentioned physical 
and radiological symptoms, it is necessary to 
confirm the presence of the fungus Aspergillus, 
the existence of elevated inflammatory markers 
in laboratory tests, and to exclude the presence 
of other pathogens and immunosuppressive dise-
ases. All six criteria have to be met concomitantly. 
The reported patient did not fulfill radiological 
or laboratory criteria [17].
In asthmatic patients, in particular with ste-
roid-dependant form of asthma, as in the reported 
patient, due to hypersensitivity to the antigen of 
Aspergillus sp., aspergillosis has the form of al-
lergic bronchopulmonary aspergillosis [18]. This 
form is suspected basing on clinical symptoms in 
individuals with a predisposing illness. The pa-
tients complain about wheezing, fever and pleural 
pain. Expectoration of secretion with black and 
brown plugs is observed in 31−69% of patients 
[8]. In imaging examinations, transient infiltra-
tions in the upper and central parts of the lung 
fields and symptoms of inflammatory thickening 
of the bronchi predominate. In computed tomo-
graphy, first of all bronchiectasis and the presence 
of mucous plugs in the lumen of the changed 
bronchi are visible. They were not present in the 
reported patient neither on examination carried 
out during hospitalisation, nor in the previously 
performed computed tomography. Typical of this 
form of aspergillosis is elevated total immunoglo-
bulin E concentration, which may be helpful in 
monitoring of the course of disease. Furthermore, 
as it was showed in the reported patient, the level 
of immunoglobulin E specific for Aspergillus sp. 
is elevated. It is worth emphasising that immu-
noglobulin E concentration remained above 2500 
IU/ml in spite of long-term therapy with steroids. 
There is no unambiguous cut-off point, above 
which concentration of specific immunoglobulin 
E should be treated as diagnostic for allergic bron-
chopulmonary aspergillosis [19−22]. According 
to diagnostic and classification criteria proposed 
by Agarwal et al. in 2013, the reported patient has 
a predisposing condition (asthma), meets both 
required immunological criteria (elevated immu-
noglobulin E concentration specific for Aspergil-
lus and total concentration of immunoglobulin 
of this class > 1000 IU/ml), but does not present 
with typical radiological changes or eosinophilia 
in the period prior to steroid therapy [8].
Patients with aspergilloma usually do not 
present any symptoms. In symptomatic patients, 
the most frequent symptom is haemoptysis being 
the result of local damage to the blood vessels 
done by mycelium and the substances it pro-
duces [13, 23, 24]. Depending on its intensity, 
haemoptysis may even lead to death. Therefore, 
due to burden related to haemoptysis, it is ne-
cessary to take into account surgical treatment, 
in particular in high-risk groups, i.e. people with 
sarcoidosis, immunosuppressed patients or those 
with increasing antibody titres against Aspergillus 
[14, 25]. The presented patient reported periodi-
cal expectoration of reddish secretion, which he 
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related to the periods of asthma exacerbations. 
Moreover, reported dyspnoea and cough are also 
attributed to infection with Aspergillus sp., and 
it is difficult to differ direct relation to infection 
with Aspergillus sp. from the symptoms of other 
concomitant lung diseases [12]. Pharmacotherapy 
in aspergilloma remains controversial. The use of 
intravenous amphotericin B does not influence 
significantly the course of disease. In case of 
abundant haemoptysis, good effects are brought 
about by the appliance of amphotericin B to the 
aspergilloma cavity. The use of oral itraconazole 
is associated with radiological and clinical im-
provement but the optimal dose and treatment 
period were not determined. Newer antifungal 
drugs such as voriconazole have not yet been 
sufficiently tested  [11−13].
Due to underlying disease and its severity, the 
reported patient was predisposed to have allergic 
bronchopulmonary aspergillosis. Despite this 
fact, aspergilloma developed in atypical localisa-
tion, without predisposing anatomical pulmonary 
changes. Therefore in diagnostic and differential 
process of steroid-dependant and severe asthma, 
it is necessary to take into account various forms 
of aspergillosis.
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